23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › MYRIAD GENETICS INC. › 2023-2024

MYRIAD GENETICS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and MYRIAD GENETICS INC.’s Form 8-K, filed June 6, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 264Asset managers, any item
  • 1,365Fund votes
  • June 6, 2024Meeting date

Results at a glance

Meeting of June 6, 2024: 4 items on MYRIAD GENETICS INC.’s Form 8-K, filed June 6, 2024: 2 approved · 2 passed (calculated).

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore MYRIAD GENETICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by MYRIAD GENETICS INC.

These tallies are MYRIAD GENETICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 6, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

MYRIAD GENETICS INC. — official shareholder meeting results, meeting held June 6, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: S. Louise Phanstiel 72,176,8196,303,67944,684 --5,899,075 92%Passed (calculated)—
Elect Director: Daniel M. Skovronsky 77,928,386557,21139,585 --5,899,075 99.3%Passed (calculated)—
2. Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024 81,454,8332,917,82951,595 ---- 97%Approved—
3. Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement 74,410,6794,060,49054,013 --5,899,075 95%Approved—

This meeting is also recorded here as June 7, 2024; both records come from the same filing, so the date should be checked against it.

Source: MYRIAD GENETICS INC., Form 8-K, filed with the SEC on June 6, 2024 — read the filing on EDGAR.

How asset managers voted at the MYRIAD GENETICS INC. 2023-2024 meeting

264 asset managers disclosed a vote on at least one MYRIAD GENETICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Daniel M. Skovronsky

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 77,928,386AGAINST: 557,211
Details: description as filed, official tally, votes by 80 asset managers

Description as filed by funds: Election of two Class I Directors to serve until the 2027 Annual Meeting of Stockholders: Daniel M. Skovronsky, M.D., Ph.D.

MYRIAD GENETICS INC.’s own tally for this item (“Elect Director: Daniel M. Skovronsky”): 77,928,386 for, 557,211 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 40,028,084 for, 4,846 against, 6,470 abstained, 68,732 not voted.

FOR
FOR: 40,028,084AGAINST: 4,846ABSTAIN: 6,470NOT VOTED: 68,732
Largest asset managers voting on “Election of two Class I Directors to serve until the 2027 Annual Meeting of Stockholders: Daniel M. Skovronsky” at MYRIAD GENETICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard13,825,0170 00For
BlackRock9,988,9270 00For
State Street3,420,5344,846 00For
Dimensional2,303,3280 00For
Fidelity1,944,1920 00For
Artisan1,612,0340 00For
TIAA1,456,0740 00For
Charles Schwab946,3730 00For
Invesco531,9260 00For
OLD WESTBURY FUNDS INC346,9310 00For
Goldman Sachs275,2080 00For
Columbia Threadneedle240,1030 00For
Equitable231,9830 00For
Jackson National212,0440 00For
Global X181,1890 00For
Allspring144,9580 00For
Direxion Shares ETF Trust143,9120 00For
Prudential/PGIM134,6080 00For
BNY Mellon129,6840 00For
QUANTITATIVE MASTER SERIES LLC124,1890 00For
FINANCIAL INVESTORS TRUST119,4760 00For
Lincoln Financial116,3990 00For
MML SERIES INVESTMENT FUND116,3790 00For
Thrivent114,0770 00For
Empower31,0410 00For

Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).

Elect Director: S. Louise Phanstiel

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 72,176,819AGAINST: 6,303,679
Details: description as filed, official tally, votes by 80 asset managers

Description as filed by funds: Election of two Class I Directors to serve until the 2027 Annual Meeting of Stockholders: S. Louise Phanstiel

MYRIAD GENETICS INC.’s own tally for this item (“Elect Director: S. Louise Phanstiel”): 72,176,819 for, 6,303,679 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 39,334,948 for, 697,982 against, 6,470 abstained, 68,732 not voted.

FOR
FOR: 39,334,948AGAINST: 697,982ABSTAIN: 6,470NOT VOTED: 68,732
Largest asset managers voting on “Election of two Class I Directors to serve until the 2027 Annual Meeting of Stockholders: S. Louise Phanstiel” at MYRIAD GENETICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard13,825,0170 00For
BlackRock9,988,9270 00For
State Street3,411,43713,943 00For
Dimensional2,303,3280 00For
Fidelity1,944,1920 00For
Artisan1,612,0340 00For
TIAA1,456,0740 00For
Charles Schwab946,3730 00For
Invesco0531,926 00Against
OLD WESTBURY FUNDS INC346,9310 00For
Goldman Sachs275,2080 00For
Columbia Threadneedle240,1030 00For
Equitable127,633104,350 00Mixed
Jackson National212,0440 00For
Global X181,1890 00For
Allspring144,9580 00For
Direxion Shares ETF Trust143,9120 00For
Prudential/PGIM134,6080 00For
BNY Mellon129,6840 00For
QUANTITATIVE MASTER SERIES LLC124,1890 00For
FINANCIAL INVESTORS TRUST119,4760 00For
Lincoln Financial116,3990 00For
MML SERIES INVESTMENT FUND116,3790 00For
Thrivent114,0770 00For
Empower31,0410 00For

Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).

Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%
FOR: 74,410,679AGAINST: 4,060,490

Prior year: 96.1% for (June 1, 2023 meeting) ▼ 1.3 pts

Details: description as filed, official tally, votes by 262 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement.

MYRIAD GENETICS INC.’s own tally for this item (“3. Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement”): 74,410,679 for, 4,060,490 against — passed, per its Form 8-K filed June 6, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 79 asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy ” at MYRIAD GENETICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard13,825,0170 00For
BlackRock9,988,9270 00For
Artisan3,668,6760 00For
State Street3,425,3800 00For
Dimensional2,303,3280 00For
Fidelity1,944,1920 00For
TIAA1,456,0740 00For
Charles Schwab946,3730 00For
Invesco0531,926 00Against
OLD WESTBURY FUNDS INC346,9310 00For
Goldman Sachs275,2080 00For
Columbia Threadneedle240,1030 00For
Equitable231,9830 00For
Jackson National212,0440 00For
Global X181,1890 00For
Allspring144,9580 00For
Direxion Shares ETF Trust143,9120 00For
Prudential/PGIM134,6080 00For
BNY Mellon129,6840 00For
QUANTITATIVE MASTER SERIES LLC124,1890 00For
FINANCIAL INVESTORS TRUST0119,476 00Against
Lincoln Financial116,3990 00For
MML SERIES INVESTMENT FUND116,3790 00For
Thrivent114,0770 00For
Empower31,0410 00For

Fund voting reports, all 79 managers: 41,424,707 for, 664,682 against, 6,470 abstained, 68,732 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 208 asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy ” at MYRIAD GENETICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Camber Capital Management LP7,485,0000 00For
Wellington6,162,6600 00For
State Street5,145,5960 00For
EARNEST PARTNERS LLC3,735,0940 00For
GLENVIEW CAPITAL MANAGEMENT, LLC3,570,2670 00For
BlackRock2,613,9050 00For
GEODE CAPITAL MANAGEMENT, LLC2,015,7000 00For
DISCIPLINED GROWTH INVESTORS INC /MN01,724,237 00Against
Nuveen1,492,8060 00For
Charles Schwab987,3200 00For
DE Shaw940,2760 00For
Northern Trust912,99554 00For
MELLON INVESTMENTS Corp672,0630 00For
Citadel660,2890 00For
PICTET ASSET MANAGEMENT SA595,2440 00For
Invesco0564,575 00Against
PRINCIPAL GLOBAL INVESTORS465,5090 00For
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO446,0610 00For
Desjardins Global Asset Management Inc.0368,877 00Against
Goldman Sachs356,9750 00For
BESSEMER INVESTMENT MANAGEMENT LLC346,9310 00For
Dimensional295,3760 00For
Natixis236,5770 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC231,2160 00For
BNY Mellon167,2870 00For

Institutional-manager reports, all 208 managers: 42,642,890 for, 3,364,966 against, 12,507 abstained, 193 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 81,454,833AGAINST: 2,917,829

Prior year: 96.6% for (June 1, 2023 meeting) unchanged

Details: description as filed, official tally, votes by 80 asset managers

Description as filed by funds: To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

MYRIAD GENETICS INC.’s own tally for this item (“2. Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024”): 81,454,833 for, 2,917,829 against — passed, per its Form 8-K filed June 6, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, was approved by stockholders.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 39,982,070 for, 50,860 against, 6,470 abstained, 68,732 not voted.

FOR
FOR: 39,982,070AGAINST: 50,860ABSTAIN: 6,470NOT VOTED: 68,732
Largest asset managers voting on “To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fisc” at MYRIAD GENETICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard13,825,0170 00For
BlackRock9,988,9270 00For
State Street3,420,7574,623 00For
Dimensional2,303,3280 00For
Fidelity1,944,1920 00For
Artisan1,612,0340 00For
TIAA1,456,0740 00For
Charles Schwab946,3730 00For
Invesco531,9260 00For
OLD WESTBURY FUNDS INC346,9310 00For
Goldman Sachs275,2080 00For
Columbia Threadneedle240,1030 00For
Equitable231,9830 00For
Jackson National212,0440 00For
Global X181,1890 00For
Allspring144,9580 00For
Direxion Shares ETF Trust143,9120 00For
Prudential/PGIM134,6080 00For
BNY Mellon129,6840 00For
QUANTITATIVE MASTER SERIES LLC124,1890 00For
FINANCIAL INVESTORS TRUST119,4760 00For
Lincoln Financial116,3990 00For
MML SERIES INVESTMENT FUND116,3790 00For
Thrivent114,0770 00For
Empower31,0410 00For

Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).

Largest MYRIAD GENETICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 90,500,000 shares outstanding at the time of that meeting.

Fund voting reports: top MYRIAD GENETICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our named executive officers, as…”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 15.28%
2BlackRock 11.04%
3Artisan 4.05%
4State Street 3.78%
5Dimensional 2.55%
6Fidelity 2.15%
7TIAA 1.61%
8Charles Schwab 1.05%
9Invesco 0.59%
10OLD WESTBURY FUNDS INC 0.38%
Institutional-manager reports: top MYRIAD GENETICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our named executive officers, as…”, 2023-2024
#Asset manager % of shares outstanding
1Camber Capital Management LP 8.27%
2Wellington 6.81%
3State Street 5.69%
4EARNEST PARTNERS LLC 4.13%
5GLENVIEW CAPITAL MANAGEMENT, LLC 3.95%
6BlackRock 2.89%
7GEODE CAPITAL MANAGEMENT, LLC 2.23%
8DISCIPLINED GROWTH INVESTORS INC /MN 1.91%
9Nuveen 1.65%
10Charles Schwab 1.09%

Reported MYRIAD GENETICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

MYRIAD GENETICS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock14,879,427 16.44%Form 13F, quarter ended March 31, 2024
Vanguard Group7,882,515 8.71%Form 13F, quarter ended March 31, 2024
State Street5,403,685 5.97%Form 13F, quarter ended March 31, 2024
Millennium Management4,294,038 4.74%Form 13F, quarter ended March 31, 2024
Morgan Stanley3,616,925 4.00%Form 13F, quarter ended March 31, 2024
Dimensional Fund Advisors2,701,514 2.99%Form 13F, quarter ended March 31, 2024
Goldman Sachs2,151,779 2.38%Form 13F, quarter ended March 31, 2024
Geode Capital2,016,372 2.23%Form 13F, quarter ended March 31, 2024
Nuveen1,431,381 1.58%Form 13F, quarter ended March 31, 2024

Percentages above are of 90,500,000 shares outstanding, as reported by MYRIAD GENETICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At MYRIAD GENETICS INC.'s shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 264 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,365 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers, as… — MYRIAD GENETICS INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: MYRIAD GENETICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 6, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from MYRIAD GENETICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

MYRIAD GENETICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “MYRIAD GENETICS (MYGN) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/myriad-genetics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.